HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-02-26Clinical Trial Update: Statin Therapy to Improve Atherosclerosis in HIV Patients [NA]
A completed Massachusetts General Hospital clinical trial assessed statin therapy to improve atherosclerosis in HIV-infected patients; resul…
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Atazanavir and Lamivudine for Treatment Simplification [Phase 4]
Phase 4 trial evaluating simplification of HIV therapy to a fixed-dose combination of atazanavir/lamivudine; results were posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-02-23Clinical Trial Update: Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241) [Phase 1]
Phase 1 study evaluating Vicriviroc's effect on HIV RNA levels in cerebrospinal fluid in HIV infections; the trial has completed.
-
FDA approval · 2015-02-20FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for ISENTRESS (raltegravir) submitted by Merck Sharp & Dohme LLC. The action updates the product…
-
FDA approval · 2015-02-20FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Isentress (raltegravir) from Merck Sharp & Dohme LLC. The approval updates labeling and/or i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2015-02-20FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Isentress (raltegravir) submitted by Merck Sharp & Dohme LLC. The action updates the product…
-
FDA approval · 2015-02-19FDA Approved: EPIVIR — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for EPIVIR (lamivudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2015-02-19FDA Approved: ZIAGEN — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for ZIAGEN (abacavir sulfate) submitted by ViiV Healthcare Company.
-
FDA approval · 2015-02-19FDA Approved: EPIVIR — Supplemental Application (ViiV Healthcare Company)
The FDA approved a supplemental application for EPIVIR (lamivudine) submitted by ViiV Healthcare Company.
-
FDA approval · 2015-02-18FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
This FDA entry announces a supplemental application for ISENTRESS (raltegravir) filed by Merck Sharp & Dohme LLC.
-
FDA approval · 2015-02-18FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for Isentress (raltegravir) from Merck, updating its labeling for HIV-1 infection.
-
FDA approval · 2015-02-18FDA Approved: ISENTRESS — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for Isentress (raltegravir) submitted by Merck Sharp & Dohme LLC. The snippet provided does not spec…
-
CLINICAL_TRIALS research · 2015-02-18Clinical Trial Update: Substance Use Disorders in HIV People of Cameroon
Clinical trial update on substance use disorders in people living with HIV in Cameroon, sponsored by Goulfey Health District Unit; the study…
-
CLINICAL_TRIALS trial_result · 2015-02-16Clinical Trial Update: Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis [Phase 3]
Phase 3 trial comparing Gentian Violet with Nystatin oral suspension for treating oropharyngeal candidiasis in HIV-1 infected individuals co…
-
CLINICAL_TRIALS trial_result · 2015-02-16Clinical Trial Update: Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome [NA]
This trial update notes completion of a study assessing whether diet-induced weight loss improves metabolic syndrome in people with HIV.
-
CLINICAL_TRIALS research · 2015-02-12Clinical Trial Update: Determining the Barriers and Motivations to Clinical Trial Participation
A completed university-led study examined barriers and motivations for enrolling in HIV clinical trials.
-
CLINICAL_TRIALS trial_result · 2015-02-10Clinical Trial Update: Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection [Phase 2]
Phase 2 trial evaluated the antiviral activity of pegylated interferon alfa-2a in chronic HIV-1 infection. Results were posted in 2015.
-
CLINICAL_TRIALS research · 2015-02-05Clinical Trial Update: Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)
This clinical trial registry reports on the long-term outcomes for HIV patients who participated in Phase 2 and 3 trials of Vicriviroc; the …
-
FDA approval · 2015-02-03FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for Prezista (darunavir) submitted by Janssen Products LP.
-
CLINICAL_TRIALS trial_result · 2015-02-03Clinical Trial Update: Evaluation of Liver Fibrosis in HIV-infected Patients With Metabolic Syndrome
This is a completed clinical trial evaluating liver fibrosis in HIV-infected patients with metabolic syndrome. The study is sponsored by Ins…
-
CLINICAL_TRIALS trial_result · 2015-02-02Clinical Trial Update: Phase I/IIa Dose-escalation Clinical Study of VAC-3S [Phase 1, Phase 2]
The Phase I/IIa dose-escalation study of VAC-3S in HIV-1 infection has completed.
-
FDA approval · 2015-01-29FDA Approved: PREZCOBIX — Original Application (Janssen Products, LP)
FDA approved PrezcoBix (darunavir ethanolate and cobicistat) on its original application for the treatment of HIV-1 infection. This represen…
-
FDA approval · 2015-01-29FDA Approved: EVOTAZ — Original Application (E.R. Squibb & Sons, L.L.C.)
FDA approved EVOTAZ, a fixed-dose combination of atazanavir and cobicistat for the treatment of HIV-1 infection, with cobicistat acting as a…
-
CLINICAL_TRIALS trial_result · 2015-01-29Clinical Trial Update: Effect of Rosuvastatin on Endothelial Function [Phase 2, Phase 3]
Phase 2/3 trial evaluating rosuvastatin's impact on endothelial function in participants with HIV infection and cardiovascular disease. The …
-
FDA approval · 2015-01-28FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for KALETRA (lopinavir/ritonavir) from AbbVie. This action signifies a supplemental NDA approval…